The clinical stage of non–small cell lung cancer as assessed by means of fluorodeoxyglucose–positron emission tomographic/computed tomographic scanning.

Slides:

Advertisements

Similar presentations

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Advertisements

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

Stephen R. Broderick, MD, MPHS

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Lung cancer screening: No more excuses

A risk factor paper on air leaks: Now it's time for treatment strategy papers from the only 5-tool hospital athlete—the thoracic surgeon Robert James.

Interventional radiology suite or hybrid operating room: Which is the best for lung nodule localization? Robert B. Cameron, MD The Journal of Thoracic.

The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients.

The True False Negative Rates of Esophageal and Endobronchial Ultrasound in the Staging of Mediastinal Lymph Nodes in Patients With Non-Small Cell Lung.

Endoscopic ultrasound-guided fine needle aspiration and endobronchial ultrasound- guided transbronchial needle aspiration: Are two better than one in mediastinal.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience Maria Teresa Congedo, MD, Alfredo Cesario,

Survival after resection of synchronous non–small cell lung cancer

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

How should we treat air leaks?

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S

Robert James Cerfolio, MD, FACS, FCCP, Ayesha S

The lord of the rings Antonio Miceli, MD, PhD

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Bartley P. Griffith, MD, FACS, FRCS

Military surgeons just want to have fun

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

A first start for lung transplantation?

Required area of lymph node sampling during segmentectomy for clinical stage IA non– small cell lung cancer Hiroaki Nomori, MD, PhD, Yasuomi Ohba, MD,

Stephen R. Broderick, MD, MPHS

Navigating the lung for hidden treasure

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Niv Ad, MD, Lawrence M. Wei, MD

Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon

Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling Alessandro Brunelli, MD, Gaetano Rocco, MD

Cardiac surgery in patients with a porcelain aorta

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

We are the company we keep: The importance of the tumor microenvironment Sai Yendamuri, MD, FACS The Journal of Thoracic and Cardiovascular Surgery

Distribution and Likelihood of Lymph Node Metastasis Based on the Lobar Location of Nonsmall-Cell Lung Cancer Robert J. Cerfolio, MD, Ayesha S. Bryant,

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Prognosis and “granularity”: Building on staging foundations?

Robert James Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

“The more things change…”: The challenges ahead

Managing conflicts of interest

Aritoshi Hattori, MD, Kenji Suzuki, MD

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Debunking dogma: The arduous task of writing AATS consensus guidelines

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

The clinical stage of non–small cell lung cancer as assessed by means of fluorodeoxyglucose–positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers Ayesha S. Bryant, MSPH, MD, Robert James Cerfolio, MD, FACS, FCCP The Journal of Thoracic and Cardiovascular Surgery Volume 132, Issue 6, Pages 1363-1368 (December 2006) DOI: 10.1016/j.jtcvs.2006.07.032 Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Distribution of false-positive and false-negative results between smokers and nonsmokers. Positron emission tomographic/computed tomographic scan results were more often false negative in patients who were current smokers. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 1363-1368DOI: (10.1016/j.jtcvs.2006.07.032) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Pack-year smoking history versus accuracy of predicting N2 lymph node disease. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 1363-1368DOI: (10.1016/j.jtcvs.2006.07.032) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Simplified hypothesis of the affect of smoking on fluorodeoxyglucose–positron emission tomographic uptake. Smokers might have a higher background fluorodeoxyglucose uptake, resulting in a decreased maxSUV of the nodule. In this example, a nodule with a maxSUV of 10 would be reported with a maxSUV of 6 in a smoker and 8 in a nonsmoker because of differences in background uptake. maxSUV, maximum standardized uptake value. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 1363-1368DOI: (10.1016/j.jtcvs.2006.07.032) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions